Reduction of nephrotoxicity and improvement of immunosuppression by combination of cyclosporine A and azathioprine.
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007674:Kidney Diseases / Q000139:chemically induced*; D016030:Kidney Transplantation; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D011897:Random Allocation; D013601:T-Lymphocytes / Q000276:immunology
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D011239:Prednisolone; D001379:Azathioprine